NYSE American - Nasdaq Real Time Price • USD
CEL-SCI Corporation (CVM)
As of 12:41 PM EDT. Market Open.
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Dec 2023) | Next Qtr. (Mar 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | -- | 1 | 2 | 2 |
| Avg. Estimate | 0 | -0.14 | -0.72 | -0.49 |
| Low Estimate | 0 | -0.14 | -0.94 | -0.61 |
| High Estimate | 0 | -0.14 | -0.51 | -0.38 |
| Year Ago EPS | -0.18 | -0.19 | -0.73 | -0.72 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Dec 2023) | Next Qtr. (Mar 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 1 | 1 | 2 | 2 |
| Avg. Estimate | -- | -- | 130k | 4.57M |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | 260k | 9.13M |
| Year Ago Sales | -- | -- | -- | 130k |
| Sales Growth (year/est) | -- | -- | -- | 3,415.40% |
Earnings History
| CURRENCY IN USD | 12/31/2022 | 3/31/2023 | 6/30/2023 | 9/30/2023 |
|---|---|---|---|---|
| EPS Est. | -0.21 | -0.17 | -0.16 | -0.16 |
| EPS Actual | -0.18 | -0.19 | -0.19 | -0.16 |
| Difference | 0.03 | -0.02 | -0.03 | 0 |
| Surprise % | 14.30% | -11.80% | -18.80% | 0.00% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Dec 2023) | Next Qtr. (Mar 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 0 | -0.14 | -0.72 | -0.49 |
| 7 Days Ago | -0.14 | -0.14 | -0.72 | -0.49 |
| 30 Days Ago | -0.14 | -0.13 | -0.71 | -0.49 |
| 60 Days Ago | -0.14 | -0.13 | -0.71 | -0.49 |
| 90 Days Ago | -0.14 | -0.13 | -0.68 | -0.51 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Dec 2023) | Next Qtr. (Mar 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | 1 | -- |
Growth Estimates
| CURRENCY IN USD | CVM | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -- | -- | -- | 1.50% |
| Next Qtr. | 26.30% | -- | -- | 11.40% |
| Current Year | 1.40% | -- | -- | 5.20% |
| Next Year | 31.90% | -- | -- | 13.40% |
| Next 5 Years (per annum) | -- | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | EF Hutton: Buy to Buy | 7/12/2023 |
| Reiterates | EF Hutton: Buy | 3/9/2023 |
| Maintains | EF Hutton: Buy | 12/29/2022 |
| Initiated | EF Hutton: Buy | 4/7/2022 |
| Initiated | HC Wainwright & Co.: Buy | 1/13/2020 |
| Initiated | Taglich Brothers: Speculative Buy | 2/20/2013 |
Related Tickers
NWBO Northwest Biotherapeutics, Inc.
0.4758
+3.41%
RVPH Reviva Pharmaceuticals Holdings, Inc.
2.9794
-1.35%
CTXR Citius Pharmaceuticals, Inc.
0.7032
-1.86%
UNCY Unicycive Therapeutics, Inc.
0.9901
-4.80%
CARM Carisma Therapeutics, Inc.
1.6450
-2.08%
ACET Adicet Bio, Inc.
1.8400
-1.86%
ATNM Actinium Pharmaceuticals, Inc.
6.80
-3.68%
OCUP Ocuphire Pharma, Inc.
1.5100
-1.31%
CYDY CytoDyn Inc.
0.1466
-1.29%
ANVS Annovis Bio, Inc.
13.38
+5.02%